Friday, June 1, 2018

PCSK9 inhibitors show superior LDL-C lowering effects to ezetimibe

Proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitor is superior to ezetimibe in reducing low-density lipoprotein cholesterol (LDL-C), with or without statin therapy, according to a study. Additionally, PCSK9 inhibitor shows comparable safety profile. 

NOACs in AF: Differences in Asians vs non-Asians

Non-vitamin K antagonist oral anticoagulants (NOACs) offer better efficacy and safety, especially in terms of risk of stroke and major bleeding, respectively than warfarin for Asian patients with atrial fibrillation (AF), according to a presentation at APSC 2018. The benefits were also greater for Asians compared with non-Asians. 

Early warning score system reduces in-hospital cardiac arrest events

Implementation of an electronic national early warning score information system may cut the rate of in-hospital cardiac arrest, as well as improve the rate of survival to discharge, as shown in a study.

Brugada, SUNDS more common in Asians

Compared to Western populations, the prevalence rates of Brugada syndrome and of sudden unexplained nocturnal death syndrome (SUNDS) are higher in Asia, particularly in the Philippines, reports Dr Giselle Gervacio.

Low ankle-brachial index tied to cognitive decline

Even in the absence of peripheral arterial disease, a lower ankle-brachial index is significantly associated with larger declines in cognitive function, according to a study.

Hypertension a heavy healthcare burden in Asia

The sum of individuals with hypertension is large and the increase in disease prevalence is pronounced, according to cardiology specialist Dr Jorge Sison. Consequently, metabolic syndrome is now more prevalent in the region.

Malay ethnicity, smoking, hyperlipidaemia predict risk of coronary calcification

Malay ethnicity, male gender, smoking and having hyperlipidemia are associated with an increased risk of coronary calcification, according to a study.

Is the new BP guideline good for Asians?

Whether the 2017 ACC/AHA* blood pressure (BP) guidelines should be adopted in Asian countries was the topic of a much-anticipated discussion at APSC 2018.

Appropriate SGLT2i use can help prevent serious AEs

The appropriate use of sodium/glucose cotransporter 2 inhibitors (SGLT2i) may prevent serious adverse events (SAEs) among Japanese patients with type 2 diabetes (T2D), according to a retrospective analysis of data from medical claim database.

What, how, when of using NOACs in practice

When making practical decision on using non-vitamin K antagonist oral anticoagulants (NOACs), several factors should be considered such as age, renal function, and risk of bleeding, according to a presentation.

Dapagliflozin drives HbA1c, SBP, and weight down in DERIVE

The use of the sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin in patients with type 2 diabetes (T2D) and moderate renal impairment provides benefits beyond glucose lowering, with no new safety signals, in phase III DERIVE* study.

PCSK9 inhibitors show superior LDL-C lowering effects to ezetimibe

Proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitor is superior to ezetimibe in reducing low-density lipoprotein cholesterol (LDL-C),...